StreetInsider.com News Articles

Form 4 Guardant Health, Inc. For: Jul 15 Filed by: Tariq Musa

Thu, 16 Jul 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260716/26780396.html

Form 4 Guardant Health, Inc. For: Jul 15 Filed by: Tariq Musa

Thu, 16 Jul 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260716/26780396.html

Form 144 Guardant Health, Inc. Filed by: Tariq Musa

Thu, 16 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260716/26779580.html

Form 144 Guardant Health, Inc. Filed by: Tariq Musa

Thu, 16 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260716/26779580.html

Guardant Health (GH) PT Raised to $190 at Guggenheim

Thu, 16 Jul 2026 06:41:31 -0400

(Updated - July 16, 2026 6:41 AM EDT)

Guggenheim analyst Subbu Nambi raised the price target on Guardant Health (NASDAQ: GH) to $190.00 (from $160.00) while maintaining a Buy rating.

The analyst commented: "Leveraging proprietary work with our data consultant, we analyzed web traffic data related to affiliated Shield URLs, including visitation and views, with additional granularity on the sources of visits and web pages that were viewed. We come away from the 2Q26 data observing robust web traction for Shield, giving us confidence in the consensus ~54K volume estimate for this quarter. We are raising our PT from $160 to $190."

Guardant Health (GH) PT Raised to $190 at Guggenheim

Thu, 16 Jul 2026 06:41:31 -0400

(Updated - July 16, 2026 6:41 AM EDT)

Guggenheim analyst Subbu Nambi raised the price target on Guardant Health (NASDAQ: GH) to $190.00 (from $160.00) while maintaining a Buy rating.

Guardant Health (GH) PT Raised to $200 at TD Cowen on 'Meaningfully Higher' Forecasts

Wed, 15 Jul 2026 10:02:42 -0400

TD Cowen analyst Dan Brennan raised the price target on Guardant Health (NASDAQ: GH) to $200.00 (from $127.00) while maintaining a Buy rating.

The analyst commented: "Catalysts Drive Sales, EBITDA & EPS Forecasts Meaningfully Higher; We updated our model for recent events (with GH up 64% from pre the 1st event). FDA G360 approval (paves way for G360 ADLT price lift) is the biggest & we also factor in UNH/Shield and ACS. Our '28 sales est increased 23% & we assume 85% of the upside drops through yielding 2030 EBITDA of $1.2B (29% margin) & $6.07 in EPS. Our new $200

Guardant Health (GH) PT Raised to $200 at TD Cowen on 'Meaningfully Higher' Forecasts

Wed, 15 Jul 2026 10:02:42 -0400

TD Cowen analyst Dan Brennan raised the price target on Guardant Health (NASDAQ: GH) to $200.00 (from $127.00) while maintaining a Buy rating.

Guardant Health (GH) PT Raised to $205 at Canaccord

Tue, 14 Jul 2026 06:42:17 -0400

Canaccord analyst Kyle Mikson raised the price target on Guardant Health (NASDAQ: GH) to $205.00 (from $135.00) while maintaining a Buy rating.

Guardant Health (GH) PT Raised to $196 at Baird

Mon, 13 Jul 2026 07:18:17 -0400

Baird analyst Catherine Schulte raised the price target on Guardant Health (NASDAQ: GH) to $196.00 (from $129.00) while maintaining a Outperform rating.

Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026

Thu, 09 Jul 2026 16:05:00 -0400

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.

About Guardant Health

Guardant Health is a leading precision oncology company focused on

Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026

Thu, 09 Jul 2026 16:05:00 -0400

Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.

About Guardant Health

Guardant Health is a leading precision oncology company focused on

Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026

Thu, 09 Jul 2026 16:05:00 -0400

Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.

About Guardant Health

Guardant Health is a leading precision oncology company focused on

Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026

Thu, 09 Jul 2026 16:05:00 -0400

Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.

About Guardant Health

Guardant Health is a leading precision oncology company focused on

Guardant Health (GH) PT Raised to $175 at Morgan Stanley

Thu, 09 Jul 2026 08:15:50 -0400

Morgan Stanley analyst Kallum Titchmarsh raised the price target on Guardant Health (NASDAQ: GH) to $175.00 (from $130.00) while maintaining a Overweight rating.

Guardant Health (GH) PT Raised to $215 at Citi

Wed, 08 Jul 2026 05:47:31 -0400

Citi analyst Patrick Donnelly raised the price target on Guardant Health (NASDAQ: GH) to $215.00 (from $150.00) while maintaining a Buy rating.

Guardant Health (GH) PT Raised to $190 at BofA Securities

Mon, 06 Jul 2026 05:56:44 -0400

BofA Securities analyst Michael Ryskin raised the price target on Guardant Health (NASDAQ: GH) to $190.00 (from $135.00) while maintaining a Buy rating.

The analyst comments "Post recent FDA / ACS wins, as well as last Wednesday’s UnitedHealth (UHC) coverage decision on Shield CRC, we’ve revisited Guardant Health (GH)’s upcoming catalysts and updated our thoughts ahead of 2Q earnings. We expect recent wins to unlock incremental volumes across Oncology and Screening franchise and drive meaningful ASP benefits in 2H’26 / 2027, and believe there’s high likelihood of a FY26 guide increase on the 2Q call. While much of the upside is

Guardant Health (GH) PT Raised to $190 at BofA Securities

Mon, 06 Jul 2026 05:56:44 -0400

BofA Securities analyst Michael Ryskin raised the price target on Guardant Health (NASDAQ: GH) to $190.00 (from $135.00) while maintaining a Buy rating.

Form 4 Guardant Health, Inc. For: Jul 01 Filed by: Monroe Terilyn J.

Thu, 02 Jul 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20260702/26729879.html

Form 4 Guardant Health, Inc. For: Jul 01 Filed by: Monroe Terilyn J.

Thu, 02 Jul 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20260702/26729879.html

Form 4 Guardant Health, Inc. For: Jul 01 Filed by: Saia John G.

Thu, 02 Jul 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20260702/26729881.html

Form 4 Guardant Health, Inc. For: Jul 01 Filed by: Saia John G.

Thu, 02 Jul 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20260702/26729881.html

Form 4 Guardant Health, Inc. For: Jul 01 Filed by: Kalia Kumud

Thu, 02 Jul 2026 18:12:00 -0400

si-local-file:///var/storage/secattach/20260702/26729875.html

Form 4 Guardant Health, Inc. For: Jul 01 Filed by: Kalia Kumud

Thu, 02 Jul 2026 18:12:00 -0400

si-local-file:///var/storage/secattach/20260702/26729875.html

Form 4 Guardant Health, Inc. For: Jul 01 Filed by: Chudova Darya

Thu, 02 Jul 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260702/26729868.html